V
Verrica Pharmaceuticals Inc. (VRCA)
NCM – Real Time Price. Currency in USD
6.84
+0.63 (10.14%)
At close: Jun 26, 2026, 4:00 PM EDT
6.84
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
6.84
+0.63 (10.14%)
At close: Jun 26, 2026, 4:00 PM EDT
6.84
0.00 (0.00%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
| Name | Position |
|---|---|
| Dr. Bradley J. Catalone MBA, Ph.D. | Head of Drug Development |
| Dr. Jayson M. Rieger M.B.A., Ph.D. | President, CEO & Director |
| Dr. Noah L. Rosenberg M.D. | Chief Medical Officer |
| Mr. Chris Chapman | Chief Commercial Officer |
| Mr. David Zawitz | COO, Chief Legal Officer & Secretary |
| Mr. Eugene Scavola | Executive Vice President of Technical Operations |
| Mr. John J. Kirby CPA | Interim Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-09 | 8-K | d139416d8k.htm |
| 2026-05-12 | S-8 | d135825ds8.htm |
| 2026-05-12 | 8-K | d152529d8k.htm |
| 2026-05-12 | 10-Q | vrca-20260331.htm |
| 2026-04-20 | DEFA14A | d28726ddefa14a.htm |
| 2026-04-20 | DEF 14A | d61950ddef14a.htm |
| 2026-04-20 | ARS | d29565dars.pdf |
| 2026-03-11 | 8-K | d94203d8k.htm |
| 2026-03-11 | 10-K | vrca-20251231.htm |
| 2025-12-30 | 8-K | d54232d8k.htm |